Pharming Group (PHAR)

• Market cap: $952M
• 1 day: 0.07%
• 5 days: -8.67%
• 1 month: 12.19%
• 3 months: 22.79%
• 6 months: 57.95%
• Year to date: 32.89%
• 1 year: 78.21%
• 5 years: -16.77%
• 10 years: -16.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Employees: 404

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

45% more capital invested

Capital invested by funds: $427K [Q1] → $620K (+$194K) [Q2]

0.08% more ownership

Funds ownership: 0.01% [Q1] → 0.09% (+0.08%) [Q2]

0% more funds holding

Funds holding: 3 [Q1] → 3 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1